{
    "root": "bbbac9d0-5bd1-44db-87c1-556d464efbe1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ibrance",
    "value": "20250314",
    "ingredients": [
        {
            "name": "PALBOCICLIB",
            "code": "G9ZF61LE7G"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "ibrance indicated treatment adult patients hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative advanced metastatic breast cancer combination : •an aromatase inhibitor initial endocrine-based therapy ; •fulvestrant patients disease progression following endocrine therapy .",
    "contraindications": "ibrance tablets taken orally without food combination aromatase inhibitor fulvestrant . ( 2 ) • recommended starting dose : 125 mg daily taken without food 21 days followed 7 days treatment . ( 2.1 ) • dosing interruption and/or dose reductions recommended based individual safety tolerability . ( 2.2 )",
    "warningsAndPrecautions": "ibrance supplied following strengths package configurations : ibrance tablets package configuration tablet strength ( mg ) ndc tablet description monthly box containing 3 weekly blister packs 7 tablets ( 21 tablets total ) 125 ndc 0069-0688-03 oval , light purple , film-coated tablets debossed `` pfizer `` one side `` pbc 125 `` side . monthly box containing 3 weekly blister packs 7 tablets ( 21 tablets total ) 100 ndc 0069-0486-03 oval , green , film-coated tablets debossed `` pfizer `` one side `` pbc 100 `` side . monthly box containing 3 weekly blister packs 7 tablets ( 21 tablets total ) 75 ndc 0069-0284-03 round , light purple , film-coated tablets debossed `` pfizer `` one side `` pbc 75 `` side .",
    "adverseReactions": "none .",
    "indications_original": "IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:\n                  \n                     \n                        •an aromatase inhibitor as initial endocrine-based therapy; or \n                     \n                        •fulvestrant in patients with disease progression following endocrine therapy.",
    "contraindications_original": "IBRANCE tablets are taken orally with or without food in combination with an aromatase inhibitor or fulvestrant. ( 2 ) • Recommended starting dose: 125 mg once daily taken with or without food for 21 days followed by 7 days off treatment. ( 2.1 ) • Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability. ( 2.2 )",
    "warningsAndPrecautions_original": "IBRANCE is supplied in the following strengths and package configurations:\n                  \n                     IBRANCE Tablets\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Tablet Strength (mg)\n                           \n                           \n                              NDC\n                           \n                           \n                              Tablet Description\n                           \n                        \n                     \n                     \n                        \n                           \n                              Monthly box containing 3 weekly blister packs of 7 tablets each (21 tablets total)\n                           \n                           \n                              125\n                           \n                           \n                              NDC 0069-0688-03\n                           \n                           \n                              Oval, light purple, film-coated tablets debossed with \"Pfizer\" on one side and \"PBC 125\" on the other side.\n                           \n                        \n                        \n                           \n                              Monthly box containing 3 weekly blister packs of 7 tablets each (21 tablets total)\n                           \n                           \n                              100\n                           \n                           \n                              NDC 0069-0486-03\n                           \n                           \n                              Oval, green, film-coated tablets debossed with \"Pfizer\" on one side and \"PBC 100\" on the other side.\n                           \n                        \n                        \n                           \n                              Monthly box containing 3 weekly blister packs of 7 tablets each (21 tablets total)\n                           \n                           \n                              75\n                           \n                           \n                              NDC 0069-0284-03\n                           \n                           \n                              Round, light purple, film-coated tablets debossed with \"Pfizer\" on one side and \"PBC 75\" on the other side.",
    "adverseReactions_original": "None."
}